Highlights

  • AFT Pharmaceuticals (ASX:AFP) reported FY26 Revenue of NZD 254.7 million.
  • FY26 operating profit reached NZD 24.4 million.
  • Net profit after tax increased 24% to NZD 14.1 million.
  • FY27 guidance targets NZD 28–32 million operating profit.

AFT Pharmaceuticals develops, licenses, markets and distributes prescription, hospital and over-the-counter medicines across Australasia and other international markets. AFT shares (ASX:AFP) changed hands at AUD 3.50 on November 17, 2026, an increase of 1.16% during the session. The company’s FY26 results highlighted higher revenue and earnings, accompanied by Investment in new markets and a larger development programme for FY27.

Medicines Portfolio and Geographic Operations

AFT sells proprietary and in-licensed products, including branded, generic and patented medicines. Its portfolio includes Maxigesic pain-relief products and therapies supplied through pharmacy and hospital channels. AFT (ASX:AFP) has commercial operations centred on Australia and New Zealand and is building international distribution and licensing activity through the United Kingdom, Europe, North America, Asia and South Africa.

The group combines product sales with Royalty and licensing income. These revenue sources can follow different schedules: domestic product sales depend on distribution and customer demand, while international product launches require local registration, distribution and Supply arrangements. Upfront and milestone licensing receipts can vary according to contract terms.

2026 International and Research Developments

In its May 2026 full-year release, AFT (ASX:AFP) described new-market activity including Combogesic IV in Canada and the broader distribution of Combogesic tablets in the United Kingdom. The company also reported integration of products acquired for its South African operations and work on European injectable medicine launches.

AFT outlined research activity in intravenous iron, dermatology, eye treatments and further injectable products. The company disclosed a China out-licensing agreement for its investigational intravenous iron medicine, with upfront, development and sales milestones and potential ongoing royalties. The underlying clinical and regulatory work must progress before such projects can be treated as established commercial medicines.

FY26 Financial Results and Revenue Mix

AFT Pharmaceuticals (ASX:AFP) reported FY26 Operating Revenue of NZD 254.7 million, up 22% from NZD 208.0 million. Product sales and royalties increased 21% to NZD 251.6 million, while licensing income was NZD 3.1 million compared with NZD 0.7 million in FY25. Australasia revenue rose 16% to NZD 210.5 million.

International product sales and royalties grew 66% to NZD 28.5 million, and Asia increased 41% to NZD 15.6 million. EBITDA reached NZD 28.8 million, compared with NZD 20.9 million, while operating profit rose to NZD 24.4 million from NZD 17.6 million. Net profit after tax increased 24% to NZD 14.1 million.

Gross Margin on product sales and royalties moved to 42.7% from 43.9%, reflecting product mix and currency effects. Net Debt increased to NZD 38.6 million from NZD 14.5 million, with working-capital requirements and South African product purchases contributing. The board declared a Dividend of NZD 2.5 cents per share, versus NZD 1.8 cents a year earlier.

FY27 Guidance and Business Risks

AFT (ASX:AFP) stated that it was targeting at least NZD 300 million of FY27 revenue and expected operating profit of NZD 28 million to NZD 32 million. It planned to raise research-and-development spending from NZD 18 million in FY26 to NZD 25 million in FY27. These are company targets and not completed financial outcomes.

Risks include product approval and launch timing, clinical outcomes, currency movements, pharmaceutical supply, regional Demand and higher working-capital needs. Product and geographic expansion may increase expenditure ahead of revenue. Progress on international operations and the ratio of operating Earnings to investment will therefore be relevant to subsequent reporting.

Operating expenses represented 33.8% of FY26 sales, versus 35.6% in FY25. This lower ratio accompanied a decline in gross margin. Both metrics will matter when assessing FY27 guidance against the costs of international expansion and research.

Key Insights

AFT (ASX:AFP) reported higher FY26 revenue and earnings alongside increased borrowing and research spending. Its FY27 objectives depend partly on international rollout and licensing activity. Future releases will show how those initiatives affect margins, cash requirements and the achievement of management guidance.